Founders of technology-based companies often recognize very early on that their company’s IP and related technology comprise a significant or
Continue Reading Emerging Companies: Framework for Leveraging Your IP & Tech

Founders of technology-based companies often recognize very early on that their company’s IP and related technology comprise a significant or…
Continue Reading Emerging Companies: Framework for Leveraging Your IP & Tech
Centripetal Networks, Inc. (“Centripetal”), one of the fastest growing innovators in the cybersecurity space, leveraged its patent portfolio against Cisco…
Continue Reading Lessons Learned From Centripetal’s Multi-Billion Dollar Damages Award Against Cisco
Quick heads up, the World Economic Forum released a Special Report covering what it considers to the the top 10…
Continue Reading World Economic Forum Releases Top 10 Emerging Technologies of 2020
As Pfizer and BioNTech announced this week that results of their COVID-19 vaccine have exceeded expectations, the technology behind the…
Continue Reading Breaking Down Moderna’s COVID-19 Patent Pledge: Why Did They Do It?
In the fast-paced and dynamic environment of startup and emerging companies, standard operating procedures and compliance matters may often fall…
Continue Reading Is it Time to Re-evaluate (or Create) Your Document Retention Policy?
At this point we have all heard how artificial intelligence (AI) will change the world, and many of us have…
Continue Reading USPTO Report Shows Tremendous Growth in Patent Filings on Artificial Intelligence
On October 22, 2020, Boston-based Atea Pharmaceuticals, Inc. (“Atea”) announced an agreement with Roche for the exclusive rights to research,…
Continue Reading Atea Pharmaceuticals Collaborates with Roche on Oral COVID-19 Therapeutic
This week, Ryder System, Inc. (NYSE: R), announced a new corporate venture capital fund called RyderVentures.
The fund seeks to…
Continue Reading Ryder Launches $50M Venture Fund for Supply Chain Startups
Founders routinely need to disclose their groundbreaking technologies to third party investors, suitors, collaborators, peers, consultants and others in order…
Continue Reading Key Considerations Regarding Early Disclosures and Patent Protection
Pharmaceutical giant Eli Lilly and Company will purchase four-year-old Disarm Therapeutics, a Cambridge-based biotechnology company, for $135 million up…
Continue Reading Eli Lilly to Buy Disarm Therapeutics for $135M Plus Potentially $1B+
We use cookies to enhance your user experience. By continuing to use this site you are giving your consent for us to use cookies. For more information, please see our Privacy Policy.